M435-1279 is a UBE2T inhibitor. M435-1279 blocks UBE2T-mediated degradation of RACK1, leading to inhibit the hyperactivation of Wnt/β-catenin signaling pathway.

97%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:45.0 mg/mL (107.3 mM)

M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of AGS, HGC27, and MKN45 cells. M435-1279 (0, 4, 8, 12, 16, 20 μM) inhibits the cell viability with IC50s of 16.8, 11.88, 7.76, 6.93 μM of GES-1, HGC27, AGS MKN45, cells, respectively. M435-1279 (31 nM to 500 μM) binds to UBE2T protein with a KD value of 50.5 μM. M435-1279 (11.88 μM; 48 h) blocks the ubiquitination of RACK1, leading to inhibit the hyperactivation of the Wnt/β-catenin pathway[1].

M435-1279 (5 mg/kg/day; intratumor injection; 18 days) slows the tumor growth. M435-1279 induces higher expression of RACK1 proteins, and lower expression of Ki-67 and β-catenin proteins in intratumor tumors[1].